Haleon plc Form 6-K Summary
Business context and reporting period
Haleon plc, a global consumer-health company listed on the LSE and NYSE, filed this Form 6-K for May 2024. The filing reports the results of the company’s Annual General Meeting held on 8 May 2024. Haleon’s principal categories include oral health, pain relief, respiratory health, digestive health, and vitamins, minerals and supplements.
Key financial and operating information
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating-period financial metrics. It records shareholder voting outcomes and approval of the final dividend, without stating the dividend amount.
Material changes versus the prior comparable period
No comparable-period financial results or material operating changes are reported. The filing reflects governance actions approved at the 2024 AGM.
AGM outcomes, outlook, risks, and unusual items
- All resolutions were approved. Resolutions 19 through 23 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.
- The final dividend was approved with 99.98% of votes cast in favor.
- The annual report and accounts were approved with 99.98% of votes cast in favor.
- The Directors’ Remuneration Report was approved with 95.74% of votes cast in favor, the lowest approval percentage among the principal ordinary resolutions.
- All directors standing for re-election were re-elected. Deirdre Mahlan received the lowest support, with 88.31% of votes cast in favor and 11.69% against.
- KPMG LLP was re-appointed as auditor with 99.79% of votes cast in favor.
- Shareholders approved authorities relating to share allotments, disapplication of pre-emption rights, shortened general-meeting notice periods, and share purchases.
- The authority to make off-market purchases of shares from Pfizer was approved with 99.90% of votes cast in favor. Pfizer did not vote its ordinary shares on this resolution.
- For most resolutions, approximately 86.8% of issued share capital voted. Resolution 23 represented 64.21% of issued share capital because Pfizer did not vote its relevant shares.
- No management guidance, outlook update, contingency, litigation matter, or unusual financial item is disclosed in the filing.
Important facts for investors to verify
- Review Haleon’s annual report and accounts for the underlying financial results, cash flow, leverage, liquidity, risks, and dividend amount.
- Confirm the final dividend amount, record date, payment date, and any applicable currency or withholding details.
- Assess the significance of the lower vote support for the remuneration report and the re-election of Deirdre Mahlan.
- Review the terms and potential implications of the approved share-purchase authorities, particularly the authority to purchase shares from Pfizer.
- Confirm the company’s issued share capital and voting-rights position, reported as 9,132,301,104 shares as of 3 May 2024.